Skip to main content

Clinical and pre-clinical evaluation of fosmidomycin and its derivates as antimalarial drugs

Objective

The present project will help to develop fosmidomycin, an inhibitor of the DOXP reductoisomerase, into an antimalarial drug. In parallel to the clinical evaluation of fosmidomycin in human volunteers, tests with derivatives of fosmidomycin with demonstrably improved pharmacological profiles in two different non-human primate models will be the pre-requisite for a straight forward clinical development of a second generation of DOXP reductoisomerase inhibitors as antimalarial drugs. Furthermore, biochemical, molecular biological and pharmacological studies will increase our knowledge about the relevance of the DOXP pathway for the survival of malaria parasites, and demonstrate its potential as a new target for chemotherapy. Finally, new DOXP reductoisomerase inhibitors with improved antimalarial activity will be developed.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

JUSTUS-LIEBIG-UNIVERSITY OF GIESSEN
Address
58,Sriedrichstr. 24
35392 Giessen
Germany

Participants (6)

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Netherlands
Address
151,Lange Kleiweg 151
2280 GH Rijswijk Zh
HOPITAL ALBERT SCHWEITZER
Gabon
Address

Lambarene
ORGANISATION DE LUTTE CONTRE LES ENDEMIES EN AFRIQUE CENTRALE
Cameroon
Address

10 Yaounde
UNIVERSIDAD DEL VALLE
Colombia
Address
Calle 4B # 36-00
Cali
UNIVERSIDADE DE SAO PAULO
Brazil
Address
Avenida Prof. Lineu Prestes 1374, Edificio Biomedi
05508-900 Sao Paulo
UNIVERSITE LOUIS PASTEUR, STRASBOURG 1
France
Address
Rue Koeberlé 3
67000 Strasbourg